比马鲁单抗可改善胰岛素抵抗个体的身体成分和胰岛素敏感性。
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.
机构信息
Diabetes Research Institute (OSR-DRI), San Raffaele Vita-Salute University, Milan, Italy.
Novartis Institutes for Biomedical Research, Basel, Switzerland.
出版信息
Diabetes Obes Metab. 2018 Jan;20(1):94-102. doi: 10.1111/dom.13042. Epub 2017 Aug 2.
AIM
To test the hypothesis that an improving body composition in insulin-resistant individuals could enhance insulin sensitivity.
METHODS
A total of 16 people with a mean body mass index of 29.3 kg/m and insulin resistance, received a single dose of bimagrumab or placebo and were assessed at week 10 for insulin sensitivity, using a hyperinsulinaemic-euglycaemic clamp and an intravenous glucose tolerance test (IVGTT), and for body composition using dual energy X-ray absorptiometry and positron-emission tomography.
RESULTS
Bimagrumab increased lean mass by 2.7% (P < .05) and reduced fat mass by 7.9% (P = .011) at week 10 compared with placebo, and had a neutral effect on body weight. Bimagrumab reduced glycated haemoglobin by 0.21% at week 18 (P < .001) and improved insulin sensitivity by ~20% (according to the clamp) to ~40% (according to the IVGTT).
CONCLUSION
Taking the observed changes together, and given that these occurred without accompanying dietary intervention and without any prescribed regular physical exercise, bimagrumab may offer a novel approach for the treatment of the metabolic complications of obesity.
目的
验证在胰岛素抵抗个体中改善身体成分可以提高胰岛素敏感性的假设。
方法
共有 16 名平均 BMI 为 29.3kg/m2 且存在胰岛素抵抗的个体接受了单次剂量的比马鲁单抗或安慰剂治疗，并在第 10 周接受评估，以评估胰岛素敏感性，使用高胰岛素-正常血糖钳夹和静脉葡萄糖耐量试验（IVGTT），并使用双能 X 射线吸收法和正电子发射断层扫描评估身体成分。
结果
与安慰剂相比，比马鲁单抗在第 10 周时增加了 2.7%的瘦体重（P<0.05），减少了 7.9%的脂肪量（P=0.011），而体重则没有明显变化。比马鲁单抗在第 18 周时降低了 0.21%的糖化血红蛋白（P<0.001），并使胰岛素敏感性提高了约 20%（根据钳夹试验）至约 40%（根据 IVGTT）。
结论
综合观察到的变化，考虑到这些变化是在没有伴随饮食干预和没有规定的定期体育锻炼的情况下发生的，比马鲁单抗可能为肥胖代谢并发症的治疗提供了一种新方法。
Zotero 插件